Key result
ESC perioperative guidelines mandate troponin surveillance in ~88% of at-risk surgical patients.
Why the study?
The 2022 ESC guidelines expanded recommendations for perioperative troponin monitoring to detect myocardial injury after non-cardiac surgery, but the clinical practice and resource implications in a secondary hospital were unclear.
Does the application of the 2022 ESC guidelines for perioperative troponin testing after non-cardiac surgery substantially increase testing demand and identify new cardiac diagnoses?
Observational (n=1,231)
No
Does the application of the 2022 ESC guidelines for perioperative troponin testing after non-cardiac surgery substantially increase testing demand and identify new cardiac diagnoses?
Applying the 2022 ESC guidelines for perioperative troponin testing in non-cardiac surgery would require testing 17% of all inpatients and identifies new cardiac events in 6% of tested patients, highlighting significant organizational and resource implications.
Answers are grounded in this paper and cite their sources.
Projects major perioperative testing burden; leaves open whether expanded troponin monitoring improves outcomes or justifies resource use.
Background and Aims Myocardial injury after non‐cardiac surgery (MINS) is a significant postoperative complication. In 2022, the European Society of Cardiology (ESC) updated its guidelines, recommending perioperative troponin monitoring for a broader surgical population. This study aimed to assess the implications of implementing these guidelines in a secondary Swiss hospital. Methods Patients meeting ESC guideline criteria for troponin testing were identified, along with those undergoing surgeries deemed similar in risk and complexity. We retrospectively analyzed all in‐patient non‐cardiac surgeries performed in 2023 ( n = 6413). Demographic data, cardiac risk factors, new cardiac diagnoses, and mortality within 3 months post‐surgery were assessed. The primary outcome was the demand for postoperative troponin testing when applying the 2022 ESC guidelines. The secondary outcome was to detect new cardiac diagnoses among patients meeting these criteria. Results Of the 6413 in‐patient surgeries, 1306 (20%) met the guideline's or study‐defined criteria for intermediate‐risk, high‐risk, or procedures similar regarding risk and complexity. After excluding ineligible patients, we analyzed data from 1231 patients, and found 1089 patients (88% of included patients; 17% of all patients) who would have required testing. Within 3 months postoperatively, we identified 72 patients (6%) who developed new cardiac conditions and 54 patients (4%) died. Surgeries outside regular hours comprised 17% of cases. Conclusion Substantial postoperative troponin testing would be required to comply with the 2022 ESC guidelines, necessitating expanded organizational capacity and resources. While the value of early detection and prevention of MINS is clear, implementation in routine clinical practice may be challenging.
No takes yet. Share an insight, caveat, or question.
Ruetsche et al. (2026) conducted an observational in Non-cardiac surgery (n=1,231). Application of 2022 ESC guidelines for perioperative troponin testing was evaluated on Demand for postoperative troponin testing. Applying the 2022 ESC guidelines would have required perioperative troponin monitoring in 88% of included at-risk patients, indicating a substantial impact on healthcare resources.
Synapse has enriched 10 related papers. Consider them for comparative context: